These last two posts from drugmanrx and Mykidsdad72 go the
These last two posts from drugmanrx and Mykidsdad72 go the the nub of the matter at least as far as how I’ve come to terms with what happened. Losing our liquidity was a terrible development and should never have happened. There is no way to sugar coat it. But given that it happened, how do you go about thinking about that?
I think in the big picture nothing has changed about the business model. In fact the business model is performing as we’ve come to expect: push the envelope on new technical applications while pivoting to new opportunities, abandoning those that don’t work out, while waiting for revenue streams to take hold for the eventual benefit of shareholders. The variable in all this is Steve. He is the human element upon which everything else depends. In that regard, after coming to terms with the emotional blunt force trauma of delisting, nothing there has changed either. Steve told us what he plans to do — submit the S1 and carry on — and there is no reason to doubt that. Steve continues to be as solid and resolute in the pursuit of his vision for QMC and for bringing value to shareholders as before. There is no empirical evidence to the contrary.
Short of the S1 to date, what we’ve seen is further evidence that the business model is in play with new applications and partnerships, continuing development of next generation solar, pressing forward with India, and growing and adaptive workforce. There is also all those declarative statements about what we are actually doing and accomplishing that defy interpretation without further clarification, but are more than just suggestive.
That is how I’ve come to terms with all this. To me, any other interpretation descends into a black hole for which to date that is no reason to contemplate or enter. I have been in this a long time but nothing compared to 2009 with I8ALOSS or before the name was changed to QMC with others. We are all more than ready for good news, starting with a return of our liquidity and hopefully accompanied with news that jump-starts a big increase in share price.
1
Quantum Materials Corp. (QTMM) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Transcosmos Achieves Recognition at Contact Center Awards Recognized for clear, goal-oriented strategy working together with clients. TOKYO /PRNewswire/ -- transcosmos is thrilled to share that the company has been awarded the Special Jury Award in the Strategy category at the Contact Center Awards 2025. This prestigious event is sponsored by the Editorial Office of...
Continue Reading
HCW Biologics Collaborates with WY Biotech on a Licensing Agreement HCW Biologics has taken an exciting step forward by entering into a license agreement with WY Biotech for a transformative preclinical immunotherapeutic product candidate. This partnership positions both companies to harness innovative technologies in the biopharmaceutical landscape. Financial Aspects of...
Continue Reading
The Buzz Behind Bucked Up®'s Limited-Edition Flavor You know, there's caffeine, and then there's Bucked Up®'s caffeine kick—it’s a whole different animal. But now they’ve spiced things up a notch with their new Hunt: Orange Cream flavor. It’s plastered on every product from their line, from Bucked Up® to the wacky-named Woke AF®. Feels like they’re saying,...
Continue Reading
The Impressive Growth of SPS Commerce SPS Commerce (NASDAQ: SPSC) has carved out a strong position in the market, consistently providing remarkable returns. Over the last 15 years, this company has outpaced average market growth by a staggering 13.26% each year, resulting in an average annual return of 25.11%. As of now, SPS Commerce enjoys a robust market capitalization...
Continue Reading
Innovating Genomic Sequencing for Newborns QIAGEN (NYSE: QGEN) is making significant strides in the field of genomic medicine by partnering with Genomics England on a remarkable initiative aimed at sequencing the genomes of newborns. This pioneering effort seeks to screen for over 200 genetic conditions, facilitating early diagnosis and intervention for rare health...
Continue Reading